Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Ewing sarcoma

An EWSR1 fusion-driven sarcoma of children and young adults; relapsed disease has few options.

Live from ClinicalTrials.gov + PubMed, fetched 2026-11-12 02:00 UTC. Every row links to its source record.

Principal investigators and study chairs named on the registry for ewing sarcoma, ranked by a published score: 3 per Phase 2+ trial they lead, 1 per other trial role, 2 per oral or late-breaking talk and 0.5 per poster in our verified 2026 meeting rows, each halved every 24 months. Paper authorship is not scored yet. PubMed counts are author name plus indication, for the top 12; names are as the registry spells them, so a common name can pool several people. Open a row for their trials and links to their papers.

Joseph Ludwig

M.D. Anderson Cancer Center

score 3

31 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT07781891 · M.D. Anderson Cancer Center · RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT

Juan C Vasquez

Pediatric Early Phase Clinical Trial Network

score 3

1 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT07830667 · Children's Oncology Group · A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat

Lung-Ji Chang

Shenzhen Geno-Immune Medical Institute

score 3

5 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT03356782 · Shenzhen Geno-Immune Medical Institute · Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Natacha ENTZ WERLE

Hopitaux Universitaires de Strasbourg

score 2.9

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT07853105 · University Hospital, Strasbourg, France · Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.

Giselle SaulnierSholler

Penn State Health Children's Hospital

score 2.6

1 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT07321912 · Milton S. Hershey Medical Center · Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Giselle Saulnier Sholler

Penn State Health Children's Hospital

score 2.5

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06465199 · Milton S. Hershey Medical Center · Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Jordan Milner

University of Florida

score 2.3

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06625190 · University of Florida · Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Bhuvana A Setty

Children's Oncology Group

score 2.1

7 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.1 = 2.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2/Ph3NCT06820957 · Children's Oncology Group · Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Matteo Trucco

Cleveland Clinic Hospital

score 2

13 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2 = 0 leading Phase 2+ trials + 2 other trial roles + 0 talks + 0 posters. 0 of 3 trials are Phase 2+.

Alice Lee

Children's Oncology Group

score 1.9

9 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.9 = 1.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

David Shulman

Dana-Farber Cancer Institute

score 1.6

21 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06709495 · David S Shulman, MD · Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Chandrika Behura

Penn State Health Children's Hospital

score 1.5

1 papers

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06541262 · Milton S. Hershey Medical Center · Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Christine M Heske

National Cancer Institute (NCI)

score 1.5

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT04890093 · National Cancer Institute (NCI) · Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Pedro Hermida de Viveiros

Northwestern University

score 1.4

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.4 = 1.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT06571734 · Northwestern University · XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

Theodore Laetsch

Children's Hospital of Philadelphia

score 1.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.3 = 1 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

Yang Yao

Shanghai 6th People's Hospital

score 1.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT05046314 · Shanghai Pharmaceuticals Holding Co., Ltd · A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Martin Ebinger

University children's hospital Tübingen

score 1

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1 = 1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06094101 · University Hospital Tuebingen · Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

Claudia Rossig

University Children´s Hospital Münster

score 1

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07897968 · Universität Münster · GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors

Peter M Anderson

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

score 1

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07695311 · Rabi Hanna · EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT

Timothy A Chan

Case Comprehensive Cancer Center, Cleveland Clinic Center for Immunotherapy and Immuno-Oncology

score 1

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07695311 · Rabi Hanna · EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT

Amy Hont

Children's National Research Institute

score 0.8

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07172958 · Children's National Research Institute · Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Holly Meany

Children's National Research Institute

score 0.8

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07172958 · Children's National Research Institute · Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Jonathan Metts

Moffitt Cancer Center

score 0.8

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07194044 · H. Lee Moffitt Cancer Center and Research Institute · Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Rebecca Epperly

St. Jude Children's Research Hospital

score 0.8

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07222735 · St. Jude Children's Research Hospital · Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Nilay Shah

Nationwide Children's Hospital

score 0.7

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT05135975 · Nationwide Children's Hospital · A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Emily Slotkin

Memorial Sloan Kettering Cancer Center

score 0.6

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

Anna Raciborska

the Institue of Mother and Child

score 0.6

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT05395741 · Institute of Mother and Child, Warsaw, Poland · Regorafenib in Patients With Refractory Primary Bone Tumors

Michael V Ortiz

Pediatric Early Phase Clinical Trial Network

score 0.6

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT05071209 · National Cancer Institute (NCI) · Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Sara Federico

St. Jude Children's Research Hospital

score 0.5

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT04901702 · St. Jude Children's Research Hospital · Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Sarah B Whittle

Pediatric Early Phase Clinical Trial Network

score 0.5

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT04851119 · Children's Oncology Group · Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Andrea T Franson

Children's Oncology Group

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04320888 · National Cancer Institute (NCI) · Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Christine A Pratilas

Children's Oncology Group

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04284774 · National Cancer Institute (NCI) · Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Patrick Grohar

Children's Hospital of Philadelphia

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT04067115 · Sarcoma Alliance for Research through Collaboration · SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

Elizabeth D Alva

Children's Oncology Group

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04195555 · National Cancer Institute (NCI) · Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Mia Weiss

Washington University School of Medicine

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.2 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

Aaron Enke

3B Pharmaceuticals GmbH

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05605522 · 3B Pharmaceuticals GmbH · A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Pablo Berlanga

Gustave Roussy, Cancer Campus, Grand Paris

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05830084 · Gustave Roussy, Cancer Campus, Grand Paris · Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

Kieuhoa T Vo

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03698994 · National Cancer Institute (NCI) · Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Meredith S Irwin

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213652 · National Cancer Institute (NCI) · Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Rajen Mody

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in ewing sarcoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03526250 · National Cancer Institute (NCI) · Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)